Lipoxen founder Gregoriadis receives prestigious Founders Award

Bio-pharmaceutical group Lipoxen (LON:LPX)has announced that its founder and current Chief Scientific Officer (CSO) Gregory Gregoriadis has received a special and prestigious Founders Award in recognition of his 40 years of founding the field of liposomes in the delivery of drugs and vaccines, and its promotion over the decades.
The award was presented at he recently held international conference at the University of British Columbia in Vancouver, Canada, focused on “Lipids, Liposomes & Membrane Biophysics.”
“I am honoured to have been recognised for my work in the extremely exciting field of liposome technology and to have received the Founders Award at this important conference,” said Gregoriadis.

Earlier this summer, Lipoxen updated investors on the lead program in its partnership with Baxter International Inc (NYSE:BAX), which it said had received positive results in preclinical models and the partners are confident in the programme’s potential to transition into clinical development.

Under the terms of the development deal, Lipoxen has the potential to receive up to US$73m in milestone payments, plus royalties as the first development candidate progresses through clinical development and commercialisation.
Baxter is also investigating the Lipoxen PSA technology for other potential factor replacement therapies in the treatment of haemophilia A, B and for patients with inhibitors. According to Lipoxen, the Factor VIII global market size is approximately US$5bn whilst the Inhibitor and Factor IX markets were US$1.2 billion and US$600 million respectively.

The company also told investors that it expects its project base to return significant license fee income going forward.
Lipoxen has three proprietary patented technology platforms - PolyXen, ImuXen, and SiRNAblate.

The proprietary ImuXen technology uses lipids, natural substances found in the human body, to entrap active ingredients - like antigens - to ensure direct delivery into the appropriate cells of the immune system.

According to Lipoxen, the use of the technology results in enhanced immune responses, which could potentially lead to single dose immunity being achieved, while reducing the side effects associated with traditional vaccines.

SiRNAblate is a delivery platform for gene silencing technology, siRNA, which stands for small interfering RNA, sometimes known as short interfering RNA or silencing RNA.